Emergex Vaccines has secured $11 million funding. Abingdon biotechnology company firm develops set-point vaccines to prevent some of the world’s most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic flu. The Series A round was led by Vickers Venture Partners. Dr Finian Tan, chairman of Vickers Venture Partners, has joined Emergex’s … Continue reading $11 million funding for Emergex Vaccines